The present invention provides a modified chemokine peptide, comprising (a) an “ELR” characteristic sequence which is situated at the N-terminus of the modified chemokine peptide, (b) a “PASQF” characteristic sequence which is neighbored to the upstream of the third cysteine counted from N-terminus of the chemokine peptide, and (c) a modification at the 17th position counted from the N-terminus of the modified chemokine peptide. Additionally, the modified chemokine peptide can be used to treat cancer and inhibit tumor growth.
